Literature DB >> 28902723

Evaluation of Transient Motion During Gadoxetic Acid-Enhanced Multiphasic Liver Magnetic Resonance Imaging Using Free-Breathing Golden-Angle Radial Sparse Parallel Magnetic Resonance Imaging.

Jeong Hee Yoon, Jeong Min Lee, Mi Hye Yu, Bo Yun Hur, Robert Grimm, Kai Tobias Block, Hersh Chandarana, Berthold Kiefer, Yohan Son.   

Abstract

OBJECTIVES: The aims of this study were to observe the pattern of transient motion after gadoxetic acid administration including incidence, onset, and duration, and to evaluate the clinical feasibility of free-breathing gadoxetic acid-enhanced liver magnetic resonance imaging using golden-angle radial sparse parallel (GRASP) imaging with respiratory gating.
MATERIALS AND METHODS: In this institutional review board-approved prospective study, 59 patients who provided informed consents were analyzed. Free-breathing dynamic T1-weighted images (T1WIs) were obtained using GRASP at 3 T after a standard dose of gadoxetic acid (0.025 mmol/kg) administration at a rate of 1 mL/s, and development of transient motion was monitored, which is defined as a distinctive respiratory frequency alteration of the self-gating MR signals. Early arterial, late arterial, and portal venous phases retrospectively reconstructed with and without respiratory gating and with different temporal resolutions (nongated 13.3-second, gated 13.3-second, gated 6-second T1WI) were evaluated for image quality and motion artifacts. Diagnostic performance in detecting focal liver lesions was compared among the 3 data sets.
RESULTS: Transient motion (mean duration, 21.5 ± 13.0 seconds) was observed in 40.0% (23/59) of patients, 73.9% (17/23) of which developed within 15 seconds after gadoxetic acid administration. On late arterial phase, motion artifacts were significantly reduced on gated 13.3-second and 6-second T1WI (3.64 ± 0.34, 3.61 ± 0.36, respectively), compared with nongated 13.3-second T1WI (3.12 ± 0.51, P < 0.0001). Overall, image quality was the highest on gated 13.3-second T1WI (3.76 ± 0.39) followed by gated 6-second and nongated 13.3-second T1WI (3.39 ± 0.55, 2.57 ± 0.57, P < 0.0001). Only gated 6-second T1WI showed significantly higher detection performance than nongated 13.3-second T1WI (figure of merit, 0.69 [0.63-0.76]) vs 0.60 [0.56-0.65], P = 0.004).
CONCLUSIONS: Transient motion developed in 40% (23/59) of patients shortly after gadoxetic acid administration, and gated free-breathing T1WI using GRASP was able to consistently provide acceptable arterial phase imaging in patients who exhibited transient motion.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28902723      PMCID: PMC6080614          DOI: 10.1097/RLI.0000000000000409

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  34 in total

1.  Usefulness of controlled aliasing in parallel imaging results in higher acceleration in gadoxetic acid-enhanced liver magnetic resonance imaging to clarify the hepatic arterial phase.

Authors:  Yang Shin Park; Chang Hee Lee; In Seong Kim; Berthold Kiefer; Seung Tae Woo; Kyeong Ah Kim; Cheol Min Park
Journal:  Invest Radiol       Date:  2014-03       Impact factor: 6.016

Review 2.  MRI of the pancreas: problem solving tool.

Authors:  Chris Heyn; Derek Sue-Chue-Lam; Kartik Jhaveri; Masoom A Haider
Journal:  J Magn Reson Imaging       Date:  2012-11       Impact factor: 4.813

3.  Improvement of gadoxetate arterial phase capture with a high spatio-temporal resolution multiphase three-dimensional SPGR-Dixon sequence.

Authors:  Thomas A Hope; Manojkumar Saranathan; Iva Petkovska; Brian A Hargreaves; Robert J Herfkens; Shreyas S Vasanawala
Journal:  J Magn Reson Imaging       Date:  2013-01-31       Impact factor: 4.813

4.  An Investigation of Transient Severe Motion Related to Gadoxetic Acid-enhanced MR Imaging.

Authors:  Utaroh Motosugi; Peter Bannas; Candice A Bookwalter; Katsuhiro Sano; Scott B Reeder
Journal:  Radiology       Date:  2015-10-16       Impact factor: 11.105

Review 5.  Hepatobiliary agents and their role in LI-RADS.

Authors:  Thomas A Hope; Kathryn J Fowler; Claude B Sirlin; Eduardo A C Costa; Judy Yee; Benjamin M Yeh; Jay P Heiken
Journal:  Abdom Imaging       Date:  2015-03

6.  Dynamic Liver Magnetic Resonance Imaging in Free-Breathing: Feasibility of a Cartesian T1-Weighted Acquisition Technique With Compressed Sensing and Additional Self-Navigation Signal for Hard-Gated and Motion-Resolved Reconstruction.

Authors:  Benjamin Kaltenbach; Andreas M Bucher; Julian L Wichmann; Dominik Nickel; Christoph Polkowski; Renate Hammerstingl; Thomas J Vogl; Boris Bodelle
Journal:  Invest Radiol       Date:  2017-11       Impact factor: 6.016

7.  Respiratory Motion-Resolved Compressed Sensing Reconstruction of Free-Breathing Radial Acquisition for Dynamic Liver Magnetic Resonance Imaging.

Authors:  Hersh Chandarana; Li Feng; Justin Ream; Annie Wang; James S Babb; Kai Tobias Block; Daniel K Sodickson; Ricardo Otazo
Journal:  Invest Radiol       Date:  2015-11       Impact factor: 6.016

8.  Cystic focal liver lesions in the adult: differential CT and MR imaging features.

Authors:  K J Mortelé; P R Ros
Journal:  Radiographics       Date:  2001 Jul-Aug       Impact factor: 5.333

Review 9.  Parallel MR imaging.

Authors:  Anagha Deshmane; Vikas Gulani; Mark A Griswold; Nicole Seiberlich
Journal:  J Magn Reson Imaging       Date:  2012-07       Impact factor: 4.813

10.  The Short Breath-Hold Technique, Controlled Aliasing in Parallel Imaging Results in Higher Acceleration, Can Be the First Step to Overcoming a Degraded Hepatic Arterial Phase in Liver Magnetic Resonance Imaging: A Prospective Randomized Control Study.

Authors:  Jung Lim Yoo; Chang Hee Lee; Yang Shin Park; Jeong Woo Kim; Jongmee Lee; Kyeong Ah Kim; Hae Young Seol; Cheol Min Park
Journal:  Invest Radiol       Date:  2016-07       Impact factor: 6.016

View more
  7 in total

1.  Second shot arterial phase to overcome degraded hepatic arterial phase in liver MR imaging.

Authors:  Yang Shin Park; Jongmee Lee; Jeong Woo Kim; Cheol Min Park; Chang Hee Lee
Journal:  Eur Radiol       Date:  2018-12-14       Impact factor: 5.315

2.  Abbreviated Gadoxetic Acid-enhanced MRI with Second-Shot Arterial Phase Imaging for Liver Metastasis Evaluation.

Authors:  Jeong Woo Kim; Chang Hee Lee; Yang Shin Park; Jongmee Lee; Kyeong Ah Kim
Journal:  Radiol Imaging Cancer       Date:  2019-09-27

Review 3.  Rapid Imaging: Recent Advances in Abdominal MRI for Reducing Acquisition Time and Its Clinical Applications.

Authors:  Jeong Hee Yoon; Marcel Dominik Nickel; Johannes M Peeters; Jeong Min Lee
Journal:  Korean J Radiol       Date:  2019-12       Impact factor: 3.500

4.  Evaluation of late arterial acquisition and image quality after gadoxetate disodium injection using the CDT-VIBE sequence.

Authors:  Fen Liu; Feng Ma; Guanlan Zhou; Chongtu Yang; Bin Xiong
Journal:  Sci Rep       Date:  2022-07-06       Impact factor: 4.996

5.  Simultaneous evaluation of perfusion and morphology using GRASP MRI in hepatic fibrosis.

Authors:  Jeong Hee Yoon; Jeong Min Lee; Mi Hye Yu; Bo Yun Hur; Robert Grimm; Steven Sourbron; Hersh Chandarana; Yohan Son; Susmita Basak; Kyoung-Bun Lee; Nam-Joon Yi; Kwang-Woong Lee; Kyung-Suk Suh
Journal:  Eur Radiol       Date:  2021-06-12       Impact factor: 5.315

6.  Respiratory motion artefacts in Gd-EOB-DTPA (Primovist/Eovist) and Gd-DOTA (Dotarem)-enhanced dynamic phase liver MRI after intensified and standard pre-scan patient preparation: A bi-institutional analysis.

Authors:  Christian Wybranski; Florian Siedek; Robert Damm; Angelos Gazis; Ortrud Wenzel; Stefan Haneder; Thorsten Persigehl; Susanne Steinhauser; Maciej Pech; Frank Fischbach; Katharina Fischbach
Journal:  PLoS One       Date:  2020-03-20       Impact factor: 3.240

7.  Respiratory anomalies associated with gadoxetate disodium and gadoterate meglumine: compressed sensing MRI revealing physiologic phenomena during the entire injection cycle.

Authors:  Carl Guillaume Glessgen; Hanns-Christian Breit; Tobias Kai Block; Elmar Max Merkle; Tobias Heye; Daniel Tobias Boll
Journal:  Eur Radiol       Date:  2021-07-29       Impact factor: 5.315

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.